JP2014533699A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533699A5
JP2014533699A5 JP2014542546A JP2014542546A JP2014533699A5 JP 2014533699 A5 JP2014533699 A5 JP 2014533699A5 JP 2014542546 A JP2014542546 A JP 2014542546A JP 2014542546 A JP2014542546 A JP 2014542546A JP 2014533699 A5 JP2014533699 A5 JP 2014533699A5
Authority
JP
Japan
Prior art keywords
cancer
independently
substituted
cycloalkyl
heteroarylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014542546A
Other languages
English (en)
Japanese (ja)
Other versions
JP6031527B2 (ja
JP2014533699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/065816 external-priority patent/WO2013078123A1/en
Publication of JP2014533699A publication Critical patent/JP2014533699A/ja
Publication of JP2014533699A5 publication Critical patent/JP2014533699A5/ja
Application granted granted Critical
Publication of JP6031527B2 publication Critical patent/JP6031527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014542546A 2011-11-21 2012-11-19 グルタミナーゼのヘテロ環式阻害剤 Expired - Fee Related JP6031527B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161562266P 2011-11-21 2011-11-21
US61/562,266 2011-11-21
US201261665370P 2012-06-28 2012-06-28
US61/665,370 2012-06-28
US201261727195P 2012-11-16 2012-11-16
US61/727,195 2012-11-16
PCT/US2012/065816 WO2013078123A1 (en) 2011-11-21 2012-11-19 Heterocyclic inhibitors of glutaminase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016178240A Division JP6329226B2 (ja) 2011-11-21 2016-09-13 グルタミナーゼのヘテロ環式阻害剤

Publications (3)

Publication Number Publication Date
JP2014533699A JP2014533699A (ja) 2014-12-15
JP2014533699A5 true JP2014533699A5 (cg-RX-API-DMAC7.html) 2015-12-17
JP6031527B2 JP6031527B2 (ja) 2016-11-24

Family

ID=48470227

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014542546A Expired - Fee Related JP6031527B2 (ja) 2011-11-21 2012-11-19 グルタミナーゼのヘテロ環式阻害剤
JP2016178240A Expired - Fee Related JP6329226B2 (ja) 2011-11-21 2016-09-13 グルタミナーゼのヘテロ環式阻害剤
JP2018080830A Expired - Fee Related JP6577623B2 (ja) 2011-11-21 2018-04-19 グルタミナーゼのヘテロ環式阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016178240A Expired - Fee Related JP6329226B2 (ja) 2011-11-21 2016-09-13 グルタミナーゼのヘテロ環式阻害剤
JP2018080830A Expired - Fee Related JP6577623B2 (ja) 2011-11-21 2018-04-19 グルタミナーゼのヘテロ環式阻害剤

Country Status (26)

Country Link
EP (2) EP2782570B1 (cg-RX-API-DMAC7.html)
JP (3) JP6031527B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190127971A (cg-RX-API-DMAC7.html)
CN (2) CN104220070B (cg-RX-API-DMAC7.html)
AR (1) AR090398A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012340866B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012129A8 (cg-RX-API-DMAC7.html)
CA (1) CA2856386C (cg-RX-API-DMAC7.html)
CY (1) CY1122707T1 (cg-RX-API-DMAC7.html)
DK (1) DK2782570T3 (cg-RX-API-DMAC7.html)
EA (2) EA201692166A1 (cg-RX-API-DMAC7.html)
ES (1) ES2761866T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192144T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047642T2 (cg-RX-API-DMAC7.html)
IL (2) IL232665A0 (cg-RX-API-DMAC7.html)
LT (1) LT2782570T (cg-RX-API-DMAC7.html)
MX (1) MX362550B (cg-RX-API-DMAC7.html)
PL (1) PL2782570T3 (cg-RX-API-DMAC7.html)
PT (1) PT2782570T (cg-RX-API-DMAC7.html)
RS (1) RS59705B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201607685SA (cg-RX-API-DMAC7.html)
SI (1) SI2782570T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900738T1 (cg-RX-API-DMAC7.html)
TW (1) TWI585084B (cg-RX-API-DMAC7.html)
WO (1) WO2013078123A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201404518B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014043633A1 (en) 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
HRP20211610T1 (hr) * 2012-11-16 2022-02-04 Calithera Biosciences, Inc. Inhibitori heterocikličke glutaminaze
MX369691B (es) 2012-11-21 2019-11-19 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de empleo.
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
US9457016B2 (en) 2013-08-29 2016-10-04 New York University Methods for treating polycystic kidney disease
WO2015061432A1 (en) * 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
KR20160100408A (ko) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
CN103880777B (zh) * 2014-03-06 2015-12-30 陕西科技大学 一种制备双噻二唑二胺的方法
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
BR112016021620A2 (pt) * 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso
CR20160497A (es) * 2014-04-30 2016-12-20 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
JP6798890B2 (ja) * 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤との併用療法
AU2015283850B2 (en) 2014-07-03 2020-06-04 Board Of Regents, University Of Texas System GLS1 inhibitors for treating disease
WO2016007647A1 (en) * 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
AU2015300825B2 (en) * 2014-08-07 2019-10-10 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
SG11201708034SA (en) * 2015-03-30 2017-10-30 Calithera Biosciences Inc Methods of administering glutaminase inhibitors
US10441587B2 (en) 2015-04-06 2019-10-15 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
WO2017004359A1 (en) 2015-06-30 2017-01-05 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
US10258619B2 (en) 2015-10-05 2019-04-16 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
GB201520959D0 (en) * 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10150753B2 (en) 2015-12-22 2018-12-11 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
EP3503893A4 (en) * 2016-08-25 2020-04-29 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINE INHIBITORS
WO2018145109A1 (en) 2017-02-06 2018-08-09 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CN107137401A (zh) * 2017-03-28 2017-09-08 刘纪君 一种治疗产后抑郁症的药物组合物
CN106860460B (zh) * 2017-03-29 2019-04-23 上海市第一人民医院 谷氨酰胺酶抑制剂cb-839在制备治疗雌激素敏感型子宫内膜癌的药物中的应用
CN110741003B (zh) 2017-06-13 2021-07-23 南京明德新药研发有限公司 作为gls1抑制剂的化合物
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
KR102649592B1 (ko) * 2021-08-18 2024-03-20 한국화학연구원 신규한 마크로사이클 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN116023375A (zh) * 2021-10-25 2023-04-28 成都苑东生物制药股份有限公司 一种杂环类衍生物、其制备方法及用途
US12337274B2 (en) 2022-07-01 2025-06-24 Saudi Arabian Oil Company Methods for absorption and desorption of carbon dioxide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US6403609B1 (en) 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US6310093B1 (en) 1997-08-29 2001-10-30 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2009017822A2 (en) * 2007-08-02 2009-02-05 Amgen Inc. Pi3 kinase modulators and methods of use
US8357705B2 (en) 2008-03-27 2013-01-22 Gruenenthal Gmbh Substituted cyclohexyldiamines
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy

Similar Documents

Publication Publication Date Title
JP2014533699A5 (cg-RX-API-DMAC7.html)
JP2016505526A5 (cg-RX-API-DMAC7.html)
JP2017517548A5 (cg-RX-API-DMAC7.html)
AU2015274361B2 (en) Combination therapy with glutaminase inhibitors
JP2016502544A5 (cg-RX-API-DMAC7.html)
JP2018529780A5 (cg-RX-API-DMAC7.html)
WO2020150417A3 (en) Compounds and compositions for treating conditions associated with sting activity
SA520411325B1 (ar) مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
JP2019526560A5 (cg-RX-API-DMAC7.html)
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
JP2020510032A5 (cg-RX-API-DMAC7.html)
KR20180021117A (ko) 아르기나제 활성 억제를 위한 조성물 및 방법
CN102497864B (zh) 用于预防或治疗由化疗诱发的疼痛的σ配体
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
JP2010500993A (ja) Hsp90活性を調節するトリアゾール化合物
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
EA200702641A1 (ru) Препараты наночастиц мезилата иматиниба
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MY161818A (en) Styrenyl derivate compounds for treating ophthalmic diseases and disorders
MX2012004848A (es) Compuestos heterociclicos triciclicos.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase